National Institute on Drug Abuse; Notice of Meeting, 61488-61489 [2024-16814]
Download as PDF
<![CDATA[
61488
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
[Document Identifier: HHS–OS—60D–0990–
New]
Agency Information Collection
Activities; Proposed Collection; Public
Comment Request
Office of the Secretary
Notice.
AGENCY:
ACTION:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human is publishing the following
summary of a proposed collection for
public comment.
DATES: Comments on the ICR must be
received on or before September 30,
2024.
ADDRESSES: Submit your comments to
Sherrette.funn@hhs.gov or by calling
(202) 264–0041 and PRA@HHS.GOV
FOR FURTHER INFORMATION CONTACT:
When submitting comments or
SUMMARY:
requesting information, please include
the document identifier 0990–New–60D
and project title for reference, to
Sherrette A. Funn, email:
Sherrette.Funn@hhs.gov, PRA@
HHS.GOV or call (202) 264–0041 the
Reports Clearance Officer.
SUPPLEMENTARY INFORMATION: Interested
persons are invited to send their
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
Title of Information Collection:
Performance and Evaluation
Measurement Systems (PEMS).
Type of Collection: New Data
Collection.
OMB No.: 0990–New.
Abstract: The U.S. Department of
Health and Human Services (HHS)
Office of Minority Health (OMH) is
requesting OMB approval for PEMS.
The proposed information collection
activity will allow OMH to collect grant
management and performance data and
disparity impact information for all
OMH-funded projects. The clearance is
needed to support data collection using
Grant Solutions, a system that enables
OMH to comply with Federal reporting
requirements and monitor and evaluate
performance by enabling the efficient
collection of performance-oriented data
tied to OMH-wide performance
reporting needs. The ability to monitor
and evaluate performance in this
manner, and to work towards
continuous program improvement are
basic functions that OMH must be able
to accomplish to carry out its mandate
with the most effective and appropriate
use of resources.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Average burden
per response
(in hours)
Total burden
hours
Disparity Impact Statement Template .....................................................
OMH Performance Progress Report .......................................................
125
125
1
4
1
1.5
125
750
Total ..................................................................................................
250
5
2.5
875
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2024–16818 Filed 7–30–24; 8:45 am]
BILLING CODE 4150–36–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
lotter on DSK11XQN23PROD with NOTICES1
Number of
responses per
respondent
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Drug Abuse.
This will be a hybrid meeting held inperson and virtually and will be open to
the public, as indicated below, with
attendance limited to space available.
Individuals who plan to attend inperson or view the virtual meeting and
need special assistance, such as sign
language interpretation or other
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
reasonable accommodations, should
notify Dr. Gillian Acca via email at
gillian.acca@nih.gov five days in
advance of the meeting. The open
session of the meeting can be accessed
from the NIH Videocast at the following
link: https://videocast.nih.gov/.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: September 11, 2024.
Closed: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant
applications.
Open: 1:00 p.m. to 5:00 p.m.
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
Agenda: Presentations and other business
of the Council.
Place: Neuroscience Center, Conference
Room 1145/1155, National Institutes of
Health, 6001 Executive Boulevard, Rockville,
MD 20852 (Hybrid Meeting).
Contact Persons:
Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director,
National Institute on Drug Abuse, NIH,
Three White Flint North, RM 09D08, 11601
Landsdown Street, Bethesda, MD 20852,
301–443–6480, sweiss@nida.nih.gov.
Gillian Acca, Ph.D., Health Science Policy
Analyst, Division of Extramural Research,
Office of Extramural Policy, National
Institute on Drug Abuse, NIH, Three White
Flint North, RM 09C70, 11601 Landsdown
Street, Bethesda, MD 20852, 301–827–
5863, gillian.acca@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to Dr. Gillian Acca via email
at gillian.acca@nih.gov. The statement
should include the name, address, telephone
number and when applicable, the business or
professional affiliation of the interested
person.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-access-
E:\FR\FM\31JYN1.SGM
31JYN1
Federal Register / Vol. 89, No. 147 / Wednesday, July 31, 2024 / Notices
security for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: July 25, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–16814 Filed 7–30–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute on Alcohol Abuse
and Alcoholism; Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Alcohol Abuse and
Alcoholism.
This will be a hybrid meeting held inperson and virtually and will be open to
the public as indicated below.
Individuals who plan to attend inperson or view the virtual meeting and
need special assistance or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
can be accessed from the NIH Videocast
at the following link: https://
videocast.nih.gov/.
A portion of this meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
17:29 Jul 30, 2024
Jkt 262001
Name of Committee: National Advisory
Council on Alcohol Abuse and Alcoholism.
Date: September 12, 2024.
Closed: 10:00 a.m. to 10:50 a.m.
Agenda: To review and evaluate grant
applications.
Open: 11:00 a.m. to 3:30 p.m.
Agenda: Presentations and other business
of the Council.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Conference Rooms A, B & C,
6700B Rockledge Drive, Bethesda, MD 20817
(Hybrid Meeting).
Contact Person: Philippe Marmillot, Ph.D.,
Director, Office of Extramural Activities,
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health,
6700B Rockledge Drive, Room 2118,
Bethesda, MD 20892, (301) 443–2861,
marmillotp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.niaaa.nih.gov/AboutNIAAA/
AdvisoryCouncil/Pages/default.aspx, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.273, Alcohol Research
Programs, National Institutes of Health, HHS)
Dated: July 25, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–16815 Filed 7–30–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
61489
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute, Special Emphasis Panel; SEP–1:
NCI Clinical and Translational Cancer
Research.
Date: September 19, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W108, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Clifford W. Schweinfest,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W108,
Rockville, Maryland 20850, 240–276–6343,
schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer
Institute, Special Emphasis Panel; SEP–4:
NCI Clinical and Translational Cancer
Research.
Date: September 24, 2024.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W264, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Ombretta Salvucci, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W264, Rockville,
Maryland 20850, 240–276–7286, salvucco@
mail.nih.gov.
Name of Committee: National Cancer
Institute, Special Emphasis Panel; Projects in
Physical Sciences and Oncology (U01)
Review.
Date: September 25, 2024.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W640, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Rockville,
Maryland 20850, 240–276–7684,
saejeong.kim@nih.gov.
Name of Committee: National Cancer
Institute, Special Emphasis Panel; Clinical
Trials Planning Program.
Date: October 4, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 89, Number 147 (Wednesday, July 31, 2024)]
[Notices]
[Pages 61488-61489]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16814]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
This will be a hybrid meeting held in-person and virtually and will
be open to the public, as indicated below, with attendance limited to
space available. Individuals who plan to attend in-person or view the
virtual meeting and need special assistance, such as sign language
interpretation or other reasonable accommodations, should notify Dr.
Gillian Acca via email at [email protected] five days in advance of
the meeting. The open session of the meeting can be accessed from the
NIH Videocast at the following link: https://videocast.nih.gov/.
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6),
title 5 U.S.C., as amended. The grant applications and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: September 11, 2024.
Closed: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant applications.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: Presentations and other business of the Council.
Place: Neuroscience Center, Conference Room 1145/1155, National
Institutes of Health, 6001 Executive Boulevard, Rockville, MD 20852
(Hybrid Meeting).
Contact Persons:
Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research,
Office of the Director, National Institute on Drug Abuse, NIH, Three
White Flint North, RM 09D08, 11601 Landsdown Street, Bethesda, MD
20852, 301-443-6480, [email protected].
Gillian Acca, Ph.D., Health Science Policy Analyst, Division of
Extramural Research, Office of Extramural Policy, National Institute
on Drug Abuse, NIH, Three White Flint North, RM 09C70, 11601
Landsdown Street, Bethesda, MD 20852, 301-827-5863,
[email protected].
Any interested person may file written comments with the
committee by forwarding the statement to Dr. Gillian Acca via email
at [email protected]. The statement should include the name,
address, telephone number and when applicable, the business or
professional affiliation of the interested person.
In the interest of security, NIH has procedures at https://
www.nih.gov/about-nih/visitor-information/campus-access-
[[Page 61489]]
security for entrance into on-campus and off-campus facilities. All
visitor vehicles, including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on campus. Visitors attending
a meeting on campus or at an off-campus federal facility will be
asked to show one form of identification (for example, a government-
issued photo ID, driver's license, or passport) and to state the
purpose of their visit.
Information is also available on the Institute's/Center's home
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: July 25, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-16814 Filed 7-30-24; 8:45 am]
BILLING CODE 4140-01-P
